Biolidics Limited (SGX:8YY)
Singapore
· Delayed Price · Currency is SGD 0.0240
+0.0010 (4.35%)
At close: Apr 2, 2025
Biolidics Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 0.78 | 1.32 | 2.49 | 2.31 | 8.91 | Upgrade
|
Other Revenue | 0.07 | 0.05 | 0.17 | 0.02 | 0.37 | Upgrade
|
| Revenue | 0.86 | 1.36 | 2.66 | 2.33 | 9.27 | Upgrade
|
Revenue Growth (YoY) | -36.96% | -48.85% | 14.26% | -74.89% | 507.89% | Upgrade
|
Cost of Revenue | 0.55 | 0.77 | 1.37 | 2.19 | 5.47 | Upgrade
|
Gross Profit | 0.31 | 0.59 | 1.3 | 0.14 | 3.8 | Upgrade
|
Selling, General & Admin | 1.95 | 1.66 | 2.89 | 1.65 | 2.76 | Upgrade
|
Research & Development | 0 | 0.03 | 0.23 | 1.09 | 0.88 | Upgrade
|
Other Operating Expenses | 1.45 | 1.05 | 2.67 | 2.33 | 3.38 | Upgrade
|
Operating Expenses | 3.49 | 3.06 | 7.06 | 6.32 | 8.02 | Upgrade
|
Operating Income | -3.19 | -2.47 | -5.76 | -6.18 | -4.21 | Upgrade
|
Interest Expense | -0.04 | -0.11 | -0.17 | -0.21 | -0.13 | Upgrade
|
Interest & Investment Income | - | 0.08 | - | 0 | 0.03 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | 0.09 | 0.08 | -0.55 | Upgrade
|
Other Non Operating Income (Expenses) | 0.02 | 0.01 | 0.03 | 0.08 | 0 | Upgrade
|
EBT Excluding Unusual Items | -3.21 | -2.49 | -5.81 | -6.22 | -4.85 | Upgrade
|
Impairment of Goodwill | - | - | -0.63 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 0.02 | - | - | - | - | Upgrade
|
Asset Writedown | - | - | -3.42 | - | -0.06 | Upgrade
|
Other Unusual Items | - | - | - | 0.18 | 0.23 | Upgrade
|
Pretax Income | -3.19 | -2.49 | -9.85 | -6.04 | -4.68 | Upgrade
|
Income Tax Expense | 0.01 | - | -0.48 | -0.06 | -0.03 | Upgrade
|
Earnings From Continuing Operations | -3.19 | -2.49 | -9.37 | -5.98 | -4.65 | Upgrade
|
Earnings From Discontinued Operations | -0.24 | - | - | - | - | Upgrade
|
Net Income | -3.43 | -2.49 | -9.37 | -5.98 | -4.65 | Upgrade
|
Net Income to Common | -3.43 | -2.49 | -9.37 | -5.98 | -4.65 | Upgrade
|
Shares Outstanding (Basic) | 981 | 593 | 282 | 265 | 257 | Upgrade
|
Shares Outstanding (Diluted) | 981 | 593 | 282 | 265 | 257 | Upgrade
|
Shares Change (YoY) | 65.44% | 110.56% | 6.21% | 3.01% | 6.17% | Upgrade
|
EPS (Basic) | -0.00 | -0.00 | -0.03 | -0.02 | -0.02 | Upgrade
|
EPS (Diluted) | -0.00 | -0.00 | -0.03 | -0.02 | -0.02 | Upgrade
|
Free Cash Flow | -0.69 | -1.97 | -3.1 | -5.07 | -2.76 | Upgrade
|
Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.01 | Upgrade
|
Gross Margin | 35.66% | 43.13% | 48.67% | 5.97% | 41.03% | Upgrade
|
Operating Margin | -371.21% | -181.34% | -216.61% | -265.22% | -45.42% | Upgrade
|
Profit Margin | -400.23% | -182.81% | -352.27% | -256.93% | -50.15% | Upgrade
|
Free Cash Flow Margin | -80.54% | -144.45% | -116.39% | -217.65% | -29.72% | Upgrade
|
EBITDA | -3.18 | -2.41 | -4.9 | -5.3 | -3.52 | Upgrade
|
EBITDA Margin | - | -177.30% | -184.10% | -227.35% | -37.91% | Upgrade
|
D&A For EBITDA | 0.01 | 0.06 | 0.87 | 0.88 | 0.7 | Upgrade
|
EBIT | -3.19 | -2.47 | -5.76 | -6.18 | -4.21 | Upgrade
|
EBIT Margin | - | -181.34% | -216.61% | -265.22% | -45.42% | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.